Clinical trials: Epirubicin
Fallopian Tube Cancer, Ovarian Cancer
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving paclitaxel and carboplatin with epirubicin is more effective than…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004934
- Testing
- carboplatin, epirubicin hydrochloride, paclitaxel
- Where
- 18 sites in United States, Belgium and 8 more
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Breast Cancer, HER2-low-expressing Breast Cancer
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
This is a single-arm, prospective, non-randomized, single-center, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HR…
- Conditions
- Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer, Neoadjuvant Therapy
- Trial name
- NCT05165225
- Testing
- Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Neoplasm, Breast Cancer
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for…
- Conditions
- Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC)
- Trial name
- FASCINATE-N (NCT05582499)
- Testing
- Dalpiciclib, Pyrotinib, SHR-A1811
- Where
- China
- Volunteers
- 716 people
- Sponsor
- Fudan University
Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve…
- Trial name
- PEONY (NCT02586025)
- Testing
- FEC Chemotherapy, Surgery, Docetaxel
- Where
- 23 sites in China, South Korea and 2 more
- Volunteers
- 329 people
- Sponsor
- Hoffmann-La Roche
Triple-Negative Breast Cancer
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Both DCb (docetaxel/carboplatin) and EC followed by D (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been recommended by NCCN guideline.
- Trial name
- NCT03154749
- Testing
- DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Lymphoma, Small Intestine Cancer
High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
RATIONALE: Giving chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them.
- Trial name
- NCT00669812
- Testing
- carmustine, cyclophosphamide, cytarabine
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Breast Cancer, Triple-negative Breast Cancer
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
This is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR)…
- Conditions
- Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
- Trial name
- NCT04138719
- Testing
- Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Epirubicin
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Hebei Medical University Fourth Hospital
T Cell Non-Hodgkin's Lymphoma
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide， epirubicin,vindesine, etoposide and prednisone) regimen as…
- Trial name
- NCT02987244
- Testing
- Chidamide, Cyclophosphamide, Epirubicin
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Breast Neoplasms
Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer
The purpose of this study is to learn how breast cancer tumors respond to a drug called Abraxane followed by a combination of 3 chemotherapy drugs commonly used for breast cancer.
- Trial name
- NCT00110695
- Testing
- Nanoparticle albumin bound paclitaxel followed by FEC
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Breast cancer is an optimal "model disease" for studying personalized medicine. Breast cancer was the first malignancy for which a predictive factor forecasting response to therapy was identified nearly 50 years ago; the…
- Trial name
- PETREMAC (NCT02624973)
- Testing
- Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
- Where
- 7 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Haukeland University Hospital
HR+/HER2- Early Breast Cancer
A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer
The purpose of this clinical trial is to evaluate the efficacy and safety of Fluzoparib combined with docetaxel in sequential paclitaxel combined with cyclophosphamide for HRD-positive, HR+/HER2- early breast cancer.
- Trial name
- NCT07162051
- Testing
- Fuzaparib, standard chemotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Xijing Hospital
Breast Cancer, TNBC - Triple-Negative Breast Cancer
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
To investigate the efficacy and safety of terbinumab combined with chemotherapy (epirubicin + cyclophosphamide → nab-paclitaxel + carboplatin) in neoadjuvant therapy of triple-negative breast cancer after HIFU.
- Trial name
- HIFU (NCT05491694)
- Testing
- Toripalimab, Epirubicin, High Intensity Focused Ultrasoun
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002953
- Testing
- cyclophosphamide, epirubicin hydrochloride, paclitaxel
- Where
- 19 sites in South Africa, United Kingdom
- Volunteers
- 704 people
- Sponsor
- Medical Research Council
Neuroendocrine Cancer
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
This study is a single prospective, parallel, double-cohort, multicenter phase II clinical trial, aiming to evaluate the efficacy and safety of ivonescimab (AK112) combined with IP chemotherapy ± TACE in the first-line treatment…
- Trial name
- NCT07712094
- Testing
- AK112, Irinotecan, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
It is a prospective and multi-center clinical research in China to compare the efficacy, safety and related impact factors between TACE alone and endovascular brachytherapy combined with stent placement and TACE for HCC with main…
- Trial name
- NCT02971345
- Testing
- Stent and Iodine-125 seed strand implantation, Stent, Iodine-125 seed
- Where
- China
- Volunteers
- 253 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer
Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer
This is an open randomized phase III study. The primary objective of this study is to compare FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated according to the patients surface area or…
- Trial name
- NCT03888677
- Testing
- 5-FU, epirubicin and cyclophosphamide
- Volunteers
- 1,535 people
- Sponsor
- Henrik Lindman
TNBC - Triple-Negative Breast Cancer
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for…
- Trial name
- NCT07256964
- Testing
- Toripalimab, PCb-EC, PCb
- Volunteers
- 216 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
RATIONALE: Chemotherapy may cause early menopause in premenopausal women. Triptorelin may prevent this from happening. PURPOSE: This randomized phase III trial is studying triptorelin to see how well it works in preventing early…
- Trial name
- NCT00311636
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 18 sites in Italy
- Volunteers
- 280 people
- Sponsor
- Gruppo Italiano Mammella (GIM)
Bladder Cancer, Non-muscle Invasive
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids
From patients with intermediate risk non-muscle invasive bladder cancer tumor (NMIBC) specimens will be harvested during transurethral resection. Fresh specimens will be cultured as patient derived organoids (PDO). After approx.
- Trial name
- GAIN-INST (NCT05024734)
- Testing
- Epirubicin, Mitomycin, Gemcitabine
- Where
- Switzerland
- Volunteers
- 31 people
- Sponsor
- Roland Seiler-Blarer